J&J says Tremfya posts sustained Crohn’s remission through 3 years in Phase 3 GALAXI studies
Johnson & Johnson disclosed new three-year Phase 3 data for Tremfya in moderate to severe Crohn’s disease. Results were set for presentation at the American College of Gastroenterology 2026 annual meeting. Patients maintained symptom control and intestinal healing through three years across both maintenance dosing regi